Trial Profile

A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-621 in Healthy Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KT 621 (Primary)
Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Eosinophilic oesophagitis; Prurigo nodularis; Rhinosinusitis
Focus Adverse reactions; First in man
Sponsors Kymera Therapeutics

02 Jun 2025 Results published in the Kymera Therapeutics Media Release.
30 May 2025 According to Kymera Therapeutics media release, the Company will host a video webcast at 8:00 a.m. ET June 2, 2025 to announce results form this trial.
09 May 2025 Status changed from recruiting to completed, according to Kymera Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com